Loading
A phase 2 trial of serplulimab in colorectal cancer, run by Zhejiang University, not yet recruiting.
16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer is a phase 2, interventional study registered as NCT07779694 by Zhejiang University, with a registry enrolment figure of 51 participants, started 2026-10-01 and due to reach its primary completion in 2028-12-31. Interventions recorded: 16-Hour Fasting; Serplulimab + chemotherapy. Conditions listed: pMMR/MSS; Locally Advanced Rectal Carcinoma; Fasting, Intermittent. Primary outcome: Pathological complete response rates. Colorectal eligibility wording from the registry: "Histological or cytological documentation of adenocarcinoma of the rectum". No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Serplulimab, Colorectal cancer trials open today (registry snapshot), Rectal cancer, Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Serplulimab, Colorectal cancer trials open today (registry snapshot), Rectal cancer, Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Serplulimab, Colorectal cancer trials open today (registry snapshot), Rectal cancer, Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Serplulimab, Colorectal cancer trials open today (registry snapshot), Rectal cancer, Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Serplulimab, Colorectal cancer trials open today (registry snapshot), Rectal cancer, Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Serplulimab, Colorectal cancer trials open today (registry snapshot), Rectal cancer, Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Serplulimab, Colorectal cancer trials open today (registry snapshot), Rectal cancer, Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Serplulimab, Colorectal cancer trials open today (registry snapshot), Rectal cancer, Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/